These tumor cells induce the expression of inhibitory receptors (ILT2/LILRB1) and downregulate the expression of NK-cell-activating receptors NKp46, NKG2D and CD16, thereby preventing recognition and killing via NK cells. This evidence concerns the gene LILRB1 and neoplasm.